Can a common muscle relaxant unlock better stroke rehab?
NCT ID NCT06666673
First seen Jun 24, 2026 · Last updated Aug 19, 2026 · Updated 3 times
Summary
This study tests how Tizanidine, a drug used for muscle stiffness, changes arm movement in people who have had a stroke. Researchers will measure brain activity, muscle responses, and movement patterns in 64 participants. The goal is to understand what limits movement after stroke, which could lead to better rehabilitation techniques.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Tizanidine (Zanaflex)
- What this could lead to
- If successful, this study could point toward better rehabilitation methods for arm movement after stroke.
- What could go wrong
- This is a very early, small study (64 people) focused on understanding brain mechanisms, not on proving a new treatment. Tizanidine is already approved for spasticity, but its effects on voluntary movement are unclear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 64 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2024
- Expected to finish
-
Jul 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * History of unilateral supratentorial ischemic stroke that occurred at least six months prior to enrollment * Age between 18-80 * Paresis confined to one side, with substantial motor impairment of the upper limb and some residual voluntary movement (Upper Extremity Fugl-Meyer Assessment in the range of 10-50/66) * Ability to communicate, understand, and provide informed consent * Ability to elevate their limb against gravity up to at least 75 degrees of shoulder flexion and to generate active elbow extension * MRI compatible * Intact skin on the hemiparetic arm * Ability to sit for three hours. Exclusion Criteria: * Motor or sensory impairment in the non-affected limb (FMA\<66, filament \>3.6) * Any brainstem and/or cerebellar lesion * untreated cardiovascular disease * History of neurologic disorder other than stroke that affects the arms * Any acute or chronic painful condition in the upper extremities or spine, indicated by a score ≥5 on a 10-point visual analog scale * Current use of a pacemaker * History of seizure * Chemo denervation: botulinum toxin injection to any portion of the paretic upper extremity within the last 6 months, or phenol/alcohol injections \<12 months before participation * Flexion contractures larger than 30 degrees in the elbow, wrist, metacarpophalangeal joints (MCP) and interphalangeal joints (IP) after stretching for 15 minutes * Current participation in any experimental rehabilitation or drug studies * Individuals with any known contraindications to Tizanidine or currently taking Tizanidine; - concurrent use of medications known to suppress central nervous system activity * pregnant women or women who are nursing. Additionally, each participant will be asked to provide a list of their current medications and a medical screening questionnaire will be sent to their primary physician. Each participant's list of medications will be reviewed for possible interactions with the study drugs and, at the study physician's advice, will be excluded from the study or asked to withhold medications when applicable. A full list of potential drug interactions can be seen in "Medication Interactions", but concisely includes the following: medications with dopaminergic, serotonergic, or noradrenergic actions; central nervous system (CNS) depressants; antihypertensive/ antiarrhythmic agents; and hormonal medications/contraceptives.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Northwestern University, Dept. of PTHMS 645 N Michigan Ave, Suite 1100
RECRUITINGChicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a checklist and heart monitor stop repeat strokes?
- Heart hole or stroke trigger? global registry tracks who gets closure and what happens next
- Zapping the spine while wearing a robotic ankle: a new way to help kids walk?
- Can a nurse and a neighbor help tame chronic disease?
- Can PET scans reveal hidden heart inflammation after a stroke?
- Two ways to catch a hidden heart rhythm after stroke